| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Apr―13 |
Corrigendum to “Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron” [Cytokine Growth Factor Rev. 70 (2023) 13-25] |
Lidong Wang, Michelle Møhlenberg, Pengfei Wang, Hao Zhou |
| 2 |
[GO] |
2023―Dec―09 |
COVID-19: from emerging variants to vaccination |
Thilini H. Senevirathne, Demi Wekking, Joseph W.R. Swain, Cinzia Solinas, Pushpamali De Silva |
| 3 |
[GO] |
2023―Nov―30 |
The impact of COVID-19 on cancer patients |
Demi Wekking, Thilini H. Senevirathne, Josie L. Pearce, Marco Aiello, Mario Scartozzi, Matteo Lambertini, Pushpamali De Silva, Cinzia Solinas |
| 4 |
[GO] |
2023―Mar―05 |
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron |
Lidong Wang, Michelle Møhlenberg, Pengfei Wang, Hao Zhou |
| 5 |
[GO] |
2022―Oct―13 |
Pharmacological therapies and drug development targeting SARS-CoV-2 infection |
Yizhou Jiang, Limor Rubin, Zhiwei Zhou, Haibo Zhang, Qiaozhu Su, Sheng-Tao Hou, Philip Lazarovici, Wenhua Zheng |
| 6 |
[GO] |
2022―Jul―07 |
Clinical progress in MSC-based therapies for the management of severe COVID-19 |
Maria Rossello-Gelabert, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez |
| 7 |
[GO] |
2022―Feb―12 |
The Coronavirus Pandemic - 2022: Viruses, Variants & Vaccines |
Magdalini Alexandridi, Julija Mazej, Enrico Palermo, John Hiscott |
| 8 |
[GO] |
2022―Jan―31 |
Roles of the Gut Microbiota in Severe SARS-CoV-2 Infection |
Yiran Liu, Dan Kuang, Dan Li, Ju Yang, Jiai Yan, Yanping Xia, Feng Zhang, Hong Cao |
| 9 |
[GO] |
2022―Jan―13 |
Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review |
Ling-Ying Lu, Po-Hao Feng, Ming-Sun Yu, Min-Chi Chen, Alex Jia-Hong Lin, Justin L. Chen, Lennex Hsueh-Lin Yu |
| 10 |
[GO] |
2022―Jan―08 |
Before the “cytokine storm”: boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications |
Somit Dutta, Amartya Mukherjee, Upendra Nongthomba |
| 11 |
[GO] |
2021―Dec―16 |
EXPLOITING NATURAL ANTIVIRAL IMMUNITY FOR THE CONTROL OF PANDEMICS: LESSONS FROM COVID-19 |
Eleonora Aricò, Laura Bracci, Luciano Castiello, Francesca Urbani, Jean-Laurent Casanova, Filippo Belardelli |
| 12 |
[GO] |
2021―Nov―15 |
SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities |
Mohammad Shah Alam, Daniel M. Czajkowsky |
| 13 |
[GO] |
2021―Oct―25 |
Cancer and Covid-19: Collectively Catastrophic |
M du Plessis, C Fourie, J Riedemann, WJS de Villiers, AM Engelbrecht |
| 14 |
[GO] |
2021―Oct―25 |
Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism |
Firdos Ahmad, Meganathan Kannan, Abdul W. Ansari |
| 15 |
[GO] |
2021―Oct―22 |
COVID-19 and dys-regulation of pulmonary endothelium: implications of vascular remodeling |
Pavitra K. Jadaun, Suvro Chatterjee |
| 16 |
[GO] |
2021―Oct―19 |
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes |
Leah Mellett, Shabaana A. Khader |
| 17 |
[GO] |
2021―Aug―02 |
ORF8a as a viroporin in SARS-CoV-2 infection? |
Milad Zandi |
| 18 |
[GO] |
2021―Jul―02 |
THE MOST RECENT SARS-CoV-2 MUTATIONS AND THEIR SUBSEQUENT VIRAL VARIANTS |
Begum Cosar, Zeynep Yagmur Karagulleoglu, Sinan Unal, Ahmet Turan Ince, Dilruba Beyza Uncuoglu, Gizem Tuncer, Bugrahan Regaip Kilinc, Yunus Emre Ozkan, Hikmet Ceyda Ozkoc, Ibrahim Naki Demir, Ali Eker, Feyzanur Karagoz, Said Yasin Simsek, Bunyamin Yasar, Mehmetcan Pala, Aysegul Demir, Irem Naz Atak, Aysegul Hanife Mendi, Vahdi Umut Bengi, Guldane Cengiz Seval, Pelin Kilic, Devrim Demir-Dora |
| 19 |
[GO] |
2021―Jun―18 |
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies |
Ni Zhao, Bin Di, Li-li Xu |
| 20 |
[GO] |
2021―Apr―15 |
COVID-19 as a Mediator of Interferon Deficiency and Hyperinflammation: Rationale for the Use of JAK1/2 Inhibitors in Combination with Interferon |
H.C. Hasselbalch, V. Skov, L. Kjær, C. Ellervik, A. Poulsen, T.D. Poulsen, C.H. Nielsen |
| 21 |
[GO] |
2021―Feb―21 |
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders |
Amruta Narayanappa, Wesley H. Chastain, Meshi Paz, Rebecca J. Solch, Isabel C. Murray-Brown, Jaime B. Befeler, Timothy E. Gressett, Michele T. Longo, Elizabeth B. Engler-Chiurazzi, Gregory Bix |
| 22 |
[GO] |
2021―Feb―10 |
Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors |
Jorge Quarleri, M. Victoria Delpino |
| 23 |
[GO] |
2021―Jan―29 |
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity |
Ghislain Opdenakker, Jo Van Damme |
| 24 |
[GO] |
2021―Jan―12 |
The Cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved |
Francesca Coperchini, Luca Chiovato, Gianluca Ricci, Laura Croce, Flavia Magri, Mario Rotondi |
| 25 |
[GO] |
2020―Dec―16 |
Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy |
Inês Barros, António Silva, Luís Pereira de Almeida, Catarina Oliveira Miranda |
| 26 |
[GO] |
2020―Dec―13 |
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy |
Jing Li, Bin Liu |
| 27 |
[GO] |
2020―Dec―01 |
SARS-CoV-2: targeted managements and vaccine development |
Moiz Bakhiet, Sebastien Taurin |
| 28 |
[GO] |
2020―Nov―05 |
Covid-19 in Brazil: A sad scenario |
Pedro Rafael D. Marinho, Gauss M. Cordeiro, Hemílio F.C. Coelho, Simone Cristina S. Brandão |
| 29 |
[GO] |
2020―Nov―04 |
Oncolytic Viral Immunotherapy in the Time of COVID-19 |
David Olagnier, Tommy Alain |
| 30 |
[GO] |
2020―Oct―23 |
A Clinical Trial of IL-15 and IL-21 Combination Therapy For COVID-19 Is Warranted |
Stephen W. Wilz |
| 31 |
[GO] |
2020―Oct―09 |
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19 |
Hamed Fouladseresht, Mehrnoosh Doroudchi, Najmeh Rokhtabnak, Hossein Abdolrahimzadehfard, Amir Roudgari, Golnar Sabetian, Shahram Paydar |
| 32 |
[GO] |
2020―Oct―08 |
Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19 |
Lucia Gabriele, Alessandra Fragale, Giulia Romagnoli, Stefania Parlato, Caterina Lapenta, Stefano Maria Santini, Keiko Ozato, Imerio Capone |
| 33 |
[GO] |
2020―Sep―21 |
Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? |
Simone Cristina Soares Brandão, Júlia de Oliveira Xavier Ramos, Luca Terracini Dompieri, Emmanuelle Tenório Albuquerque Madruga Godoi, José Luiz Figueiredo, Emanuel Sávio Cavalcanti Sarinho, Sarvesh Chelvanambi, Masanori Aikawa |
| 34 |
[GO] |
2020―Sep―09 |
AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm |
Sebastiano Gangemi, Alessandro Tonacci |
| 35 |
[GO] |
2020―Aug―25 |
Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19 |
Zhigang Hu, Sijia Li, Xinyu Song |
| 36 |
[GO] |
2020―Aug―25 |
Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic |
Anil Kumar Rana, Shubham Nilkanth Rahmatkar, Amit Kumar, Damanpreet Singh |
| 37 |
[GO] |
2020―Jul―18 |
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella |
Francesco Prattichizzo, Massimiliano Bonafè, Angelica Giuliani, Andrea Costantini, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri |
| 38 |
[GO] |
2020―Jul―04 |
Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? |
Eleonora Aricò, Laura Bracci, Luciano Castiello, Sandra Gessani, Filippo Belardelli |
| 39 |
[GO] |
2020―Jul―01 |
Cytokine Storm in COVID-19 patients transforms to a Cytokine Super Cyclone in patients with risk factors |
Betcy Susan Johnson, Malini Laloraya |
| 40 |
[GO] |
2020―Jun―24 |
A critical evaluation of glucocorticoids in the treatment of severe COVID-19 |
Cinzia Solinas, Laura Perra, Marco Aiello, Edoardo Migliori, Nicola Petrosillo |
| 41 |
[GO] |
2020―Jun―20 |
Overview of the COVID-19 and JAK/STAT Pathway Inhibition: Ruxolitinib Perspective |
Bakiye Goker Bagca, Cigir Biray Avci |
| 42 |
[GO] |
2020―Jun―11 |
Should we unstress SARS-CoV-2 infected cells? |
Fabiana Csukasi, Gustavo Rico, Jose Becerra, Ivan Duran |
| 43 |
[GO] |
2020―Jun―07 |
COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu? |
Mohamed A. Eldeeb, Faraz S. Hussain, Zaeem A. Siddiqi |
| 44 |
[GO] |
2020―Jun―06 |
IL-15 immunotherapy is a viable strategy for COVID-19 |
Hemanth Kumar Kandikattu, Sathisha Upparahalli Venkateshaiah, Sandeep Kumar, Anil Mishra |
| 45 |
[GO] |
2020―Jun―04 |
Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” |
Eugenia Quiros-Roldan, Giorgio Biasiotto, Isabella Zanella |
| 46 |
[GO] |
2020―Jun―02 |
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease |
Víctor J. Costela-Ruiz, Rebeca Illescas-Montes, Jose M. Puerta-Puerta, Concepción Ruiz, Lucia Melguizo-Rodríguez |
| 47 |
[GO] |
2020―May―28 |
The global impact of the coronavirus pandemic |
John Hiscott, Magdalini Alexandridi, Michela Muscolini, Evelyne Tassone, Enrico Palermo, Maria Soultsioti, Alessandra Zevini |
| 48 |
[GO] |
2020―May―20 |
IL-6: relevance for immunopathology of SARS-CoV-2 |
E.O. Gubernatorova, E.A. Gorshkova, A.I. Polinova, M.D. Drutskaya |
| 49 |
[GO] |
2020―May―20 |
Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? |
Cecilia T. Costiniuk, Mohammad-Ali Jenabian |
| 50 |
[GO] |
2020―May―13 |
The Covid-19 pandemic in Denmark: Big lessons from a small country |
David Olagnier, Trine H. Mogensen |
| 51 |
[GO] |
2020―May―11 |
The Cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system |
Francesca Coperchini, Luca Chiovato, Laura Croce, Flavia Magri, Mario Rotondi |
| 52 |
[GO] |
2020―May―07 |
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons |
Shivraj Hariram Nile, Arti Nile, Jiayin Qiu, Lin Li, Xu Jia, Guoyin Kai |
| 53 |
[GO] |
2020―May―06 |
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients |
Begum Dariya, Ganji Purnachandra Nagaraju |
| 54 |
[GO] |
2020―May―04 |
Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes |
Massimiliano Bonafè, Francesco Prattichizzo, Angelica Giuliani, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri |
| 55 |
[GO] |
2020―Apr―25 |
Cytokine storm intervention in the early stages of COVID-19 pneumonia |
Xinjuan Sun, Tianyuan Wang, Dayong Cai, Zhiwei Hu, Jin’an Chen, Hui Liao, Liming Zhi, Hongxia Wei, Zhihong Zhang, Yuying Qiu, Jing Wang, Aiping Wang |
